Industry Insights: Contractors, Manufacturers, and Lab Services
The below companies have invested in unique offerings to meet the needs of customers accross all segments of the life sciences industry
“AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities. While continuous processing is well known at the large-scale commercial stage, AFC also has the unique capability to provide validated GMP synthesis at small to medium scales. This helps bridge the gap for customers rather than having to make that big jump between small-scale clinical to commercial.”
Jeff Butler, President, AMPAC Fine Chemicals, an SK pharmteco company
“The Department of Defense’s Chemical and Biological Defense Small Business Innovation Research (SBIR) program awarded us an SBIR contract to continue developing a combination product of atropine and scopolamine. We recognize the threat of chemical and biological warfare to soldiers, and this grant allows us to develop products that start in the lab by executing the appropriate animal model studies to determine the dose and efficacy of that combination product.”
Mike Radomsky, President, CMC Pharmaceuticals
“CRL’s E-Rapid Transfer Port (ERTP) has recently gained additional popularity due to the aseptic trend to isolate and minimize any type of interaction inside the sterile environment. Initially, our ERTP product was more geared towards the nuclear industry, but in recent revisions, we have adapted it to the pharmaceutical market.”
Chris Gooding, Vice President and General Manager, Central Research Laboratories (CRL)
“Our most recent acquisitions were two consulting firms. One, formerly known as BioPharma Global, provides consulting services primarily for FDA submission and CMC support and specializes in assisting foreign companies with submitting their products to US regulatory bodies. The other acquisition was Meridian BioGroup, also a consulting firm providing localized services. These acquisitions aim to expand our services to provide more comprehensive solutions to Pace clients. In the past, we had to refer clients elsewhere for consulting services, but now we can offer a complete package of end-to-end services.”
Greg Kupp, President, Pace Life Sciences
“We make equipment for radiopharmaceuticals, and we have gained recognition for that. In addition, we have also expanded our role to include distributing radiopharmaceuticals, with a focus on automating the process. Automation is essential in radiopharmaceuticals, as human intervention must be limited to protect workers from radiation exposure.”
Luciano Calenti, Founder and CEO, ACIC Pharmaceuticals
“In addition to our leadership and innovation within the RTU pharmaceutical componentry space, our company is also a leader in safe and environmentally friendly pharmaceutical and medical device sterilization. Today, we offer the market steam and dry heat sterilization options. We are excited to announce that in 2023 we will also be one of the first companies to offer contract hydrogen peroxide vapor sterilization for customers that require low-temperature sterilization options.”
Daniel Prince, CEO, Prince Sterilization Services
“BFS technology is attractive from a respiratory and ophthalmic perspective, but beyond that, we have seen increased demand for our services specifically in the diagnostic space. Covid-19 shone the light on home diagnostic care and the use of reagents to complete home tests and kits. From a drug pricing reform perspective, BFS is a cost-effective way to manufacture pharmaceutical products.”
Paul Josephs, President and CEO, Woodstock Sterile Solutions
“About 90% of the medicines consumed daily in the US are generic and most of these products are supplied by overseas manufacturers. There is high demand for low-cost high-quality products and we can eliminate complexities in the supply chain as well as our dependence on foreign-supplied medicines by increasing generic drug manufacturing capabilities in the US.”
Tim Crew, CEO, Lannett Company
“Scorpius works closely with CDMO clients to develop effective regulatory drug development strategies for advanced biological therapies. Our Kansas facility will be built in accordance with our San Antonio facility to ensure that we can go from pre-clinical to commercialization employing similar platform technologies and minimizing any compliance or technology challenges that may arise.”
Mike Fiske, Vice President, Manufacturing Sciences, Scorpius BioManufacturing
“Polymers mainly used for contraceptive or hormone replacements are growing, such as local drug delivery in the ocular space or in oncology, particularly in the past 18 months. The widespread adoption of polymers for several industries is driving solid growth in the coming years. We can extrude very tight-tolerance products, which is key in this space.”
Tony Listro, VP, Technology and Site Lead, Sever Pharma Solutions
“In 2022, our growth focus has been in the areas of OTC drugs, dietary supplements, and solid-dose Rx pharmaceuticals, which will continue to be a focus for us as we move forward into 2023.”
Jeff Reingold, COO, Contract Pharmacal Corp (CPC)
